Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Highlights in breast cancer from ESMO 2021

Cristina Saura Manich • 29 Sep 2021
ESMO 2021
Breast Cancer
DESTINY-Breast03 KEYNOTE-522 MONALEESA-2

Cristina Saura Manich, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, comments on key clinical trials presented at ESMO 2021, namely the DESTINY-Breast03 study (NCT03529110), the MONALEESA-2 trial (NCT01958021) and the KEYNOTE-522 trial (NCT03036488). This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

More from Cristina Saura Manich

1:55
Advances in treatments for HER2-positive metastatic breast cancer
Cristina Saura Manich • 29 Sep 2021
2:00
TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer
Cristina Saura Manich • 29 Sep 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals